Article Sidebar
Main Article Content
Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients
Main Article Content
Abstract
Background/Aims: Distinct virological relapse (VR) has occurred after stopping the use of nucleos(t)ide analogues treatment in patients with chronic hepatitis B (CHB) who are positive for Hepatitis B e antigen (HBeAg). Here, we aimed to identify serum miR-146a and miR155 in HBeAg-positive patients with CHB and their relationship with VR after entecavir (ETV) discontinuance.
Materials and Methods: Ninety-eight patients with CHB and positive for HBeAg before initiating treatment were analyzed. Virological relapse was defined as 2 consecutive examinations (3 months apart) after treatment discontinuance, both showing an HBV DNA load of more than >2000 IU/mL.
Results: Compared to control, CHB patients were observed with increases in serum miR-146a and miR-155 before starting ETV treatment (P < .001). There were 52 patients (53.1%) experiencing VR at 12 months after discontinuance of ETV treatment. The VR group was demonstrated with increases in serum miR-146a and miR-155 than the non-VR group before starting ETV treatment (P < .001). Whether at the beginning of ETV discontinuance or at 12 months after ETV discontinuance, the VR group was noted with elevations in serum miR-146a and miR-155 than the non-VR group (P < .001).
Conclusion: The findings demonstrated that miR-146a and miR-155 levels in the circulation may be promising assessment tools for identifying sustained-virological responders after ETV discontinuance in CHB patients.
Cite this article as: Xu ML, Wang LH. Serum miR-146a and miR-155 as predictors of virological control after entecavir withdrawal in HBeAg-positive chronic hepatitis B Patients. Turk J Gastroenterol. Published online March 18, 2025. doi 10.5152/tjg.2025.24685.
Article Details
References
1. Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039-1052. [CrossRef]
2. Howell J, Seaman C, Wallace J, et al. Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology. 2023;78(3):976-990. [CrossRef]
3. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. [CrossRef]
4. Chen PJ. Challenges for hepatitis B control in Asia-Pacific areas: consolidating vaccination and rolling-out antiviral therapies. J Gastroenterol Hepatol. 2024;39(6):1033-1039. [CrossRef]
5. Kiremitçi S, Koçhan K, Seven G, et al. Results of Nucleos(t)ide analog treatment discontinuation in hepatitis B e-antigen-negative chronic hepatitis B: NUCSTOP study. Turk J Gastroenterol. 2024;35(1):17-26. [CrossRef]
6. Lai JCT, Colombatto P, Wong GLH, Brunetto MR. Why and when could nucleos(t)ide analogues treatment be withdrawn? Dig Liver Dis. Published online October 28, 2024. [CrossRef]
7. Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353-390. [CrossRef]
8. Sonneveld MJ, Park JY, Kaewdech A, et al. Prediction of sustained response after Nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE). Clin Gastroenterol Hepatol. 2022;20(4):e784-e793. [CrossRef]
9. Tan B, Liu M, Wang L, et al. Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy. Int J Infect Dis. 2021;108:37-44. [CrossRef]
10. Wakasugi H, Takahashi H, Niinuma T, et al. Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment. Cancer Lett. 2018;434:91-100. [CrossRef]
11. Fu L, Fu X, Mo J, Li X, Li R, Peng S. miR-146a-5p enhances hepatitis B virus replication through autophagy to promote aggravation of chronic hepatitis B. IUBMB Life. 2019;71(9):1336-1346. [CrossRef]
12. Fang J, Zhuge L, Rao H, Huang S, Jin L, Li J. Increased levels of miR-155 are related to higher T-cell activation in the peripheral blood of patients with chronic hepatitis B. Genet Test Mol Biomarkers. 2019;23(2):118-123. [CrossRef]
13. Hefzy EM, Hassuna NA, Shaker OG, et al. miR-155 T/A (rs767649) and miR-146a A/G (rs57095329) single nucleotide polymorphisms as risk factors for chronic hepatitis B virus infection among Egyptian patients. PLoS One. 2021;16(8):e0256724. [CrossRef]
14. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98. [CrossRef]
15. Deng Y, Kang H, Xiang H, et al. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis. JHEP Rep. 2024;6(7):101091. [CrossRef]
16. Li JF, Dai XP, Zhang W, et al. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. mBio. 2015;6(2):e02459-14. [CrossRef]
17. Niu LJ, Huang T, Wang L, Sun XF, Zhang YM. HBX suppresses PTEN to promote the malignant progression of hepatocellular carcinoma through mi-R155 activation. Ann Hepatol. 2022;27(3):100688. [CrossRef]
18. Dai CY, Tseng TC, Wong GLH, et al. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother. 2013;68(10):2332-2338. [CrossRef]
19. Huang L, Zhou L, Gan J, et al. IL-21 is associated with virological relapse of HBeAg positive chronic hepatitis B after discontinuance of entecavir. Turk J Gastroenterol. 2021;32(2):178-186. [CrossRef]
20. Sun F, Li Z, Hu L, et al. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection. Front Immunol. 2022;13:1082091. [CrossRef]
21. Brunetto MR, Cavallone D, Oliveri F, et al. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. PLoS One. 2014;9(10):e110782. [CrossRef]
22. Wang Y, Li Y. miR-146 promotes HBV replication and expression by targeting ZEB2. Biomed Pharmacother. 2018;99:576-582. [CrossRef]
23. Liu Y, Qin L, Wang J, et al. miR-146a maintains immune tolerance of Kupffer cells and facilitates hepatitis B virus persistence in mice. J Immunol. 2022;208(11):2558-2572. [CrossRef]
24. Ji M, Mei X, Jing X, Xu X, Chen X, Pan W. The cooperative complex of Argonaute-2 and microRNA-146a regulates hepatitis B virus replication through flap endonuclease 1. Life Sci. 2020;257:118089. [CrossRef]
25. Chen L, Ming X, Li W, et al. The microRNA-155 mediates hepatitis B virus replication by reinforcing SOCS1 signalling-induced autophagy. Cell Biochem Funct. 2020;38(4):436-442. [CrossRef]
26. Song X, Tan S, Wu Z, et al. HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation. Int J Cancer. 2018;143(12):3120-3130. [CrossRef]
27. Fei Y, Wang Z, Huang M, et al. MiR-155 regulates M2 polarization of hepatitis B virus-infected tumour-associated macrophages which in turn regulates the malignant progression of hepatocellular carcinoma. J Viral Hepat. 2023;30(5):417-426. [CrossRef]
28. Zhang Y, Li X, Zhang Y, et al. Pegylated interferon-alpha inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155. Ann Hepatol. 2019;18(3):494-500. [CrossRef]
29. Pan P, Li J, Lin W, Long G. Effects of resveratrol on hepatitis B virus replication: in vitro and in vivo experiments. Intervirology. 2022;65(4):206-214. [CrossRef]